[Clinical course of COVID-19 in patients with neuromuscular diseases: a multicenter study in Argentina]

Individuals with neuromuscular diseases (NMDs) were considered highly vulnerable during the COVID-19 pandemic due to respiratory and functional impairment. However, local data from Argentina are scarce. The objective was to describe the clinical course and access to the health system in an active cohort of people with NMD treated at two specialized centers in the City of Buenos Aires.

Observational, descriptive, cross-sectional study using a self-administered survey (August 2022-April 2023) in adults with confirmed NMDs and respiratory involvement under regular follow-up. Sociodemographic, functional, clinical, vaccination, and COVID-19-related outcomes were collected.

Of 120 invitations, 82 patients responded (68%). Half used ventilatory support ≥ 6 h/day. COVID-19 was confirmed in 37%; most had mild symptoms, and no deaths occurred. A total of 97.5% (80/82) had received ≥2 vaccine doses, and 58% had completed four doses. Participants reported 513 healthcare interactions, with a high proportion of remote consultations.

In this cohort, high vaccination coverage, specialized follow-up, and sustained healthcare access were associated with a generally favorable clinical course of COVID-19, even in patients with severe respiratory impairment. These findings highlight the importance of ensuring continuity of care and prioritizing vaccination in vulnerable populations.